CommercialCoverageLow impact
Niktimvo (axatilimab-csfr)
Blue Cross & Blue Shield of Mississippi·MS · Oncology, Hematology·Medical Policy
Effective date
Sep 1, 2025
We identified it
Jun 20, 2026
Summary
BCBS Mississippi has issued a new policy stating that Niktimvo (axatilimab-csfr) is NOT medically necessary for chronic graft-versus-host disease treatment, as other covered options exist. The drug requires prior authorization through BCBSMS PA review process.
Action Required
Immediately: Alert providers that Niktimvo (axatilimab-csfr) injections using HCPCS code J9038 are considered not medically necessary by BCBS Mississippi and will likely be denied. If prescribing is necessary, obtain prior authorization through BCBSMS PA review process before administration. Update billing system to flag J9038 claims for MS BCBS plans.